BioInvent treats first patient in phase II study of myeloma drug
The study will assess disease activity subsequent to treatment with BI-505 in around 10 patients. Safety, pharmacokinetics and assessment of biomarkers are the secondary objectives of the study.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.